FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385612214> ?p ?o ?g. }

• W4385612214 endingPage "1818" @default.
• W4385612214 startingPage "1809" @default.
• W4385612214 abstract "Pyrotinib, an irreversible pan-ErbB inhibitor, has been approved for treating HER2-positive advanced breast cancer in China. We conducted a nationwide, prospective observational study to examine the real-world data of pyrotinib-based therapy in this population. Patients from 61 sites across China were included. Pyrotinib-based regimens were prescribed at local physician's discretion. Demographics, treatment patterns, prognosis and safety were evaluated. The primary outcome was real-world progression-free survival (rwPFS). Of 1129 patients, pyrotinib-based therapy was prescribed as first-, second- and third- or later-line treatment in 437 (38.7%), 476 (42.2%) and 216 (19.1%) patients, respectively. Median rwPFS (mrwPFS) was 14.3 (95% CI, 13.3-15.2) months in the total population, with the longest mrwPFS of 17.8 (95% CI, 15.2-24.9) months in the first-line setting, followed by 14.4 (95% CI, 12.9-15.3) months in the second-line setting. Patients with third- or later-line treatment also achieved a mrwPFS of 9.3 (95% CI, 8.4-11.8) months. Patients with trastuzumab- or trastuzumab-pertuzumab-treated disease achieved a mrwPFS of 14.3 and 13.6 months, respectively. Dual HER2 blockade with pyrotinib plus trastuzumab showed a mrwPFS of 16.2 months in the total population, with data not mature in the first-line setting. For patients with baseline brain metastases, the mrwPFS was 11.7 months. The most common adverse event was diarrhea (any grade, 73.5%; grade ≥ 3, 15.3%). In real world, pyrotinib-based therapy shows promising effectiveness in the first-, as well as second- and later-line treatment, with acceptable tolerability. Further investigations regarding front-line use or novel combinations of pyrotinib might facilitate to maximize its anti-tumor potential." @default.
• W4385612214 created "2023-08-06" @default.
• W4385612214 creator A5000432967 @default.
• W4385612214 creator A5002426407 @default.
• W4385612214 creator A5007312763 @default.
• W4385612214 creator A5008475639 @default.
• W4385612214 creator A5011344369 @default.
• W4385612214 creator A5024007101 @default.
• W4385612214 creator A5027475930 @default.
• W4385612214 creator A5043782874 @default.
• W4385612214 creator A5045878405 @default.
• W4385612214 creator A5046091921 @default.
• W4385612214 creator A5053985637 @default.
• W4385612214 creator A5056018018 @default.
• W4385612214 creator A5056497965 @default.
• W4385612214 creator A5062017281 @default.
• W4385612214 creator A5078170751 @default.
• W4385612214 creator A5091530007 @default.
• W4385612214 date "2023-08-06" @default.
• W4385612214 modified "2023-09-30" @default.
• W4385612214 title "Real‐world treatment patterns and outcomes of pyrotinib‐based therapy in patients with <scp>HER2</scp>‐positive advanced breast cancer (<scp>PRETTY</scp>): A nationwide, prospective, observational study" @default.
• W4385612214 cites W2074048861 @default.
• W4385612214 cites W2095156669 @default.
• W4385612214 cites W2101824720 @default.
• W4385612214 cites W2105940636 @default.
• W4385612214 cites W2110444464 @default.
• W4385612214 cites W2127714076 @default.
• W4385612214 cites W2159967578 @default.
• W4385612214 cites W2166199281 @default.
• W4385612214 cites W2806209829 @default.
• W4385612214 cites W2915663023 @default.
• W4385612214 cites W2921590809 @default.
• W4385612214 cites W2969604985 @default.
• W4385612214 cites W2971837858 @default.
• W4385612214 cites W2995808512 @default.
• W4385612214 cites W3000643213 @default.
• W4385612214 cites W3043096450 @default.
• W4385612214 cites W3044204256 @default.
• W4385612214 cites W3096671135 @default.
• W4385612214 cites W3122861570 @default.
• W4385612214 cites W3127064904 @default.
• W4385612214 cites W3191648960 @default.
• W4385612214 cites W3201149630 @default.
• W4385612214 cites W3207557929 @default.
• W4385612214 cites W4206666777 @default.
• W4385612214 cites W4220685273 @default.
• W4385612214 cites W4221041876 @default.
• W4385612214 cites W4226051140 @default.
• W4385612214 cites W4241868283 @default.
• W4385612214 cites W4281675214 @default.
• W4385612214 cites W4285596493 @default.
• W4385612214 cites W4288068270 @default.
• W4385612214 cites W4293515066 @default.
• W4385612214 cites W4297537228 @default.
• W4385612214 cites W4297986262 @default.
• W4385612214 cites W4328112200 @default.
• W4385612214 cites W4376155517 @default.
• W4385612214 doi "https://doi.org/10.1002/ijc.34676" @default.
• W4385612214 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37543965" @default.
• W4385612214 hasPublicationYear "2023" @default.
• W4385612214 type Work @default.
• W4385612214 citedByCount "0" @default.
• W4385612214 crossrefType "journal-article" @default.
• W4385612214 hasAuthorship W4385612214A5000432967 @default.
• W4385612214 hasAuthorship W4385612214A5002426407 @default.
• W4385612214 hasAuthorship W4385612214A5007312763 @default.
• W4385612214 hasAuthorship W4385612214A5008475639 @default.
• W4385612214 hasAuthorship W4385612214A5011344369 @default.
• W4385612214 hasAuthorship W4385612214A5024007101 @default.
• W4385612214 hasAuthorship W4385612214A5027475930 @default.
• W4385612214 hasAuthorship W4385612214A5043782874 @default.
• W4385612214 hasAuthorship W4385612214A5045878405 @default.
• W4385612214 hasAuthorship W4385612214A5046091921 @default.
• W4385612214 hasAuthorship W4385612214A5053985637 @default.
• W4385612214 hasAuthorship W4385612214A5056018018 @default.
• W4385612214 hasAuthorship W4385612214A5056497965 @default.
• W4385612214 hasAuthorship W4385612214A5062017281 @default.
• W4385612214 hasAuthorship W4385612214A5078170751 @default.
• W4385612214 hasAuthorship W4385612214A5091530007 @default.
• W4385612214 hasBestOaLocation W43856122141 @default.
• W4385612214 hasConcept C121608353 @default.
• W4385612214 hasConcept C126322002 @default.
• W4385612214 hasConcept C197934379 @default.
• W4385612214 hasConcept C23131810 @default.
• W4385612214 hasConcept C2779786085 @default.
• W4385612214 hasConcept C2908647359 @default.
• W4385612214 hasConcept C530470458 @default.
• W4385612214 hasConcept C71924100 @default.
• W4385612214 hasConcept C99454951 @default.
• W4385612214 hasConceptScore W4385612214C121608353 @default.
• W4385612214 hasConceptScore W4385612214C126322002 @default.
• W4385612214 hasConceptScore W4385612214C197934379 @default.
• W4385612214 hasConceptScore W4385612214C23131810 @default.
• W4385612214 hasConceptScore W4385612214C2779786085 @default.
• W4385612214 hasConceptScore W4385612214C2908647359 @default.
• W4385612214 hasConceptScore W4385612214C530470458 @default.
• W4385612214 hasConceptScore W4385612214C71924100 @default.
• W4385612214 hasConceptScore W4385612214C99454951 @default.

• next